Barclays PLC Esperion Therapeutics, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 309,671 shares of ESPR stock, worth $721,533. This represents 0.0% of its overall portfolio holdings.

Number of Shares
309,671
Previous 309,671 -0.0%
Holding current value
$721,533
Previous $510,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$1.61 - $2.73 $248,759 - $421,809
154,509 Added 99.58%
309,671 $510,000
Q2 2024

Aug 14, 2024
BUY
$1.84 - $3.24 $93,247 - $164,196
50,678 Added 48.5%
155,162 $344,000
Q1 2024

May 15, 2024
SELL
$2.02 - $3.02 $33,532 - $50,132
-16,600 Reduced 13.71%
104,484 $280,000
Q4 2023

Feb 15, 2024
BUY
$0.73 - $3.08 $23,433 - $98,868
32,100 Added 36.07%
121,084 $362,000
Q3 2023

Nov 07, 2023
SELL
$0.96 - $1.79 $14,077 - $26,248
-14,664 Reduced 14.15%
88,984 $87,000
Q2 2023

Aug 03, 2023
SELL
$1.2 - $1.76 $68,134 - $99,931
-56,779 Reduced 35.39%
103,648 $144,000
Q1 2023

May 04, 2023
SELL
$1.46 - $7.3 $3,787 - $18,936
-2,594 Reduced 1.59%
160,427 $255,000
Q4 2022

Feb 13, 2023
BUY
$5.09 - $8.5 $617,544 - $1.03 Million
121,325 Added 290.98%
163,021 $1.02 Million
Q3 2022

Nov 03, 2022
BUY
$5.45 - $8.13 $74,212 - $110,706
13,617 Added 48.5%
41,696 $280,000
Q2 2022

Aug 12, 2022
SELL
$4.77 - $6.67 $33,308 - $46,576
-6,983 Reduced 19.92%
28,079 $178,000
Q1 2022

May 16, 2022
SELL
$3.34 - $5.56 $202,524 - $337,136
-60,636 Reduced 63.36%
35,062 $163,000
Q4 2021

Feb 14, 2022
BUY
$4.81 - $11.92 $226,512 - $561,336
47,092 Added 96.89%
95,698 $480,000
Q3 2021

Nov 09, 2021
BUY
$11.34 - $21.37 $162,162 - $305,591
14,300 Added 41.68%
48,606 $585,000
Q2 2021

Aug 13, 2021
SELL
$19.4 - $28.71 $72,051 - $106,628
-3,714 Reduced 9.77%
34,306 $726,000
Q1 2021

May 13, 2021
SELL
$25.12 - $36.89 $442,237 - $649,448
-17,605 Reduced 31.65%
38,020 $1.07 Million
Q4 2020

Feb 11, 2021
BUY
$24.2 - $35.76 $1.06 Million - $1.57 Million
43,764 Added 368.97%
55,625 $1.45 Million
Q3 2020

Nov 12, 2020
SELL
$31.18 - $52.71 $5.4 Million - $9.14 Million
-173,332 Reduced 93.6%
11,861 $441,000
Q2 2020

Aug 12, 2020
BUY
$30.04 - $51.31 $179,789 - $307,090
5,985 Added 3.34%
185,193 $9.5 Million
Q1 2020

May 13, 2020
BUY
$27.44 - $73.84 $1.95 Million - $5.26 Million
71,195 Added 65.91%
179,208 $5.65 Million
Q4 2019

Feb 10, 2020
BUY
$35.4 - $59.82 $2.95 Million - $4.99 Million
83,406 Added 338.95%
108,013 $6.44 Million
Q3 2019

Nov 14, 2019
SELL
$34.47 - $47.53 $258,352 - $356,237
-7,495 Reduced 23.35%
24,607 $903,000
Q2 2019

Aug 14, 2019
BUY
$40.1 - $52.33 $966,730 - $1.26 Million
24,108 Added 301.58%
32,102 $1.49 Million
Q1 2019

May 15, 2019
SELL
$40.11 - $53.57 $132,924 - $177,530
-3,314 Reduced 29.31%
7,994 $321,000
Q4 2018

Feb 14, 2019
BUY
$36.99 - $59.11 $100,982 - $161,370
2,730 Added 31.83%
11,308 $520,000
Q3 2018

Nov 14, 2018
BUY
$40.74 - $51.41 $101,483 - $128,062
2,491 Added 40.92%
8,578 $381,000
Q2 2018

Aug 14, 2018
SELL
$36.2 - $76.4 $712,886 - $1.5 Million
-19,693 Reduced 76.39%
6,087 $239,000
Q1 2018

May 15, 2018
SELL
$65.94 - $80.76 $2.63 Million - $3.22 Million
-39,917 Reduced 60.76%
25,780 $1.86 Million
Q4 2017

Feb 14, 2018
BUY
$43.47 - $67.43 $2.79 Million - $4.33 Million
64,158 Added 4168.81%
65,697 $4.33 Million
Q3 2017

Nov 14, 2017
BUY
$43.8 - $52.77 $67,408 - $81,213
1,539
1,539 $77,000

Others Institutions Holding ESPR

# of Institutions
207
Shares Held
128M
Call Options Held
1.67M
Put Options Held
930K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $155M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email